Comparative Pharmacology
Head-to-head clinical analysis: HYCODAN versus NOVRAD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYCODAN versus NOVRAD.
HYCODAN vs NOVRAD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a full mu-opioid receptor agonist; homatropine is an anticholinergic agent that reduces excessive respiratory tract secretions.
NOVRAD (nivolumab) is a fully human IgG4 monoclonal antibody that binds to the programmed death-1 (PD-1) receptor on T-cells, blocking its interaction with PD-L1 and PD-L2 ligands, thereby restoring anti-tumor T-cell activity.
1 tablet (5 mg hydrocodone/1.5 mg homatropine) orally every 4 to 6 hours as needed for cough; maximum 6 tablets per 24 hours.
8 mg/kg IV every 8 hours or 12 mg/kg IV every 12 hours; not to exceed 1200 mg per dose.
None Documented
None Documented
Terminal elimination half-life of hydrocodone is 3.8-5.7 hours (mean 4.5 h) in adults; clinical duration of analgesia is 4-6 hours. Half-life may be prolonged in hepatic or renal impairment.
Terminal elimination half-life is approximately 4-6 hours in adults with normal renal function. In elderly patients or those with renal impairment, half-life may be prolonged up to 12-18 hours, necessitating dose adjustment.
Renal elimination of unchanged drug (hydrocodone: ~26%; homatropine: negligible) and glucuronide conjugates (hydrocodone: ~40% as hydromorphone and norhydrocodone). Biliary/fecal excretion accounts for ~20-30%.
Primarily renal excretion (65-75% unchanged), with approximately 20-25% biliary/fecal elimination.
Category C
Category C
Opioid Antitussive
Opioid Antitussive